Key result
Sulforaphane suppresses cardiomyocyte hypertrophy in vitro and in vivo by downregulating GATA4/6 transcription factors and MAPK signaling pathways.
Why the study?
Does sulforaphane suppress cardiac hypertrophy in preclinical models?
Does sulforaphane suppress cardiac hypertrophy in preclinical models?
Sulforaphane shows potential as a therapeutic agent to prevent cardiac hypertrophy through downregulation of GATA4/6 and MAPK signaling pathways in preclinical models.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice; hypothesis-generating for sulforaphane in hypertrophy models.
SCOPE: Sulforaphane (SFN) is a naturally occurring isothiocynate compound found in cruciferous vegetables. Here, we report the effect of SFN on cardiac hypertrophy and propose an underlying mechanism. METHODS AND RESULTS: SFN suppresses cardiomyocyte hypertrophy induced by hypertrophic stimuli in vitro and in vivo. SFN suppresses the expression of fetal genes, including atrial natriuretic peptide, brain natriuretic peptide, and beta myosin heavy chain. We used an siRNA technique and atrial natriuretic peptide promoter with mutated GATA binding sites to demonstrate that SFN mediates cardiac hypertrophy by modulating transcription factors GATA4/6. CONCLUSION: These results suggest that SFN has the potential to prevent cardiac hypertrophy by downregulating GATA4/6 and mitogen-activated protein kinase signaling pathways.
No takes yet. Share an insight, caveat, or question.
Kee et al. (2014) studied Cardiac hypertrophy. Sulforaphane (SFN) was evaluated on Cardiomyocyte hypertrophy and expression of fetal genes. Sulforaphane suppresses cardiomyocyte hypertrophy in vitro and in vivo by downregulating GATA4/6 transcription factors and MAPK signaling pathways.
Synapse has enriched 10 related papers. Consider them for comparative context: